Clinical features of Parkinson’s disease patients are associated with therapeutic misconception and willingness to participate in clinical trials

Table 5 Spearman correlation coefficients of individual statements and the score for the “Therapeutic misconception” factor

Statement	r
Usually CTs are aimed primarily at seeking the best medication for the research participants	0.703
I would participate in CTs, because then I would receive the best treatment for me	0.673
I would like to participate in CTs in order to determine the continuation of my current treatment relationship	0.643
In CTs, all participants always receive a new effective agent	0.638
In CTs, the physician conducting the research may choose which drug the participant receives	0.564
Often, the patient participating in the research may choose which drug they receive	0.540
I would participate only in a CT in which at least one of the drugs being compared has been shown to be effective	0.525
I would participate in a CT only if the treating physician also is the investigator	0.485
I would participate in a CT if that guaranteed me new and improved medication	0.476
I would like to participate in a CT because then I would receive more thorough monitoring relative to standard treatment	0.469
I would participate in a CT only if I were not satisfied with my current medication	0.468
In CTs, the physician conducting the research is aware of whether the participant is receiving a new drug, a placebo (which does not include an effective agent), or an older Parkinson’s disease medication	0.437